Connect Biopharma is trading 75.40% up at $1.74 after positive topline results announced September 30, 2026, from its Phase 2 COPD study of rademikibart.
- The trial met its primary endpoint: treatment failure fell 81% through Week 4 versus placebo.
- The company reported fewer new COPD exacerbations and emergency visits or hospital admissions, with no new safety signals.
- No volume figure was provided.